Why Are Psychedelic Stocks Falling? (MindMed, Atai, Cybin, FieldTrip, Compass Pathways)

Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES

Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202

In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.

In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.

This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.

The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.

Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.

Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.

Links:
Psilocybin Study
https://www.science.org/doi/10.1126/sciadv.abh2399#F5

Psilocybin article
https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage

Ayahuasca study:
https://pubmed.ncbi.nlm.nih.gov/34822961/

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com
Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Psilocybin #DMT #Psychedelics

In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).

Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting. 

Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.

Excitingly, Mindset is moving towards beginning clinical trials in 2022.

On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs. 

In the long term, this deal has great potential for Otsuka. 

To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:

Can psychedelics treat mental illnesses such as depression?

Are next-generation psychedelics better than the originals?

What is happening in the brain when a person takes psychedelics?

Enjoy the episode!

You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.

*To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/

#MindsetPharma #DMT #microdosing

Hey guys! As Promised, we’re live streaming the MindMed (MMED / MMEDF ) Earnings Conference Call.

What we’re expecting to hear and discuss later is any clinical trial updates for MindMed, updates for Project Lucy and Project Layla and perhaps their potential Nasdaq Uplisitng !

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release…​

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​ ​#MindmedStock​​​ #MMEDNews

Powered by Restream https://restream.io/

Today is MindMed’s (MMED /MMEDF / MMQ) Conference call

#Mindmed #MMED #MindmedConferenceCall

Digital Therapeutics and Psychedelic Medicines || MindMed’s SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai’s secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.

Instead of doing our usual “This Week In Psychedelic Stocks episode”, I decided to discuss the article entitled “Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP” as it pertains to MindMed and Atai and because there wasn’t a lot of interesting news for our usual Psychedelic segment.

Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there’s two reasons.

1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com

Time Stamps:

0:00 – Intro
10:08 – Implications for MindMed and Atai

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #MMEDNews

Today’s episode for you focuses on why C-O FOUNDER and CEO JR Rahn founded Mindmed and on Reconstructing how we treat mental health in America.

MindMed, (MMED) on the Canadian NEO Stock exchange and (MMEDF) on the American Over the counter market has been experiencing a pull back lately. Remember what I said before: MindMed should be looked as a long term investment and is not for investors with weak stomachs!

During his recent appearance on Context 360 with Kevin O’Leary, MindMed’s Co-Ceo Jr Rahn made a sober prediction that the mental health crisis will only get worse.
-automation, sped up by the Rona virus, will depend our crisis of identity, and cause millions more to suffer. If we do nothing now, soon we could be living in a very dark world
-to reiterate a couple alarming stats; 40% have has a mental health incident or have addiction and 11% have considered committing suicide. This is terrifying, and only going to get worse. MindMed was founded with the vision to find a solution or rather multiple solutions to these mental problems. If successful, the company stands to take the biotech industry by storm and we, as psychedelic investors, will reap the returns.

https://www.youtube.com/watch?v=mNfq6eEUT7Q&t=459s&ab_channel=ContextLive

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF